2. Academic Validation
  3. A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance

A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance

  • Nat Cancer. 2024 Jul 11. doi: 10.1038/s43018-024-00781-6.
Christopher E Whitehead # 1 2,  Elizabeth K Ziemke # 1,  Christy L Frankowski-McGregor # 1,  Rachel A Mumby 1,  June Chung 1,  Jinju Li 3,  Nathaniel Osher 3,  Oluwadara Coker 4,  Veerabhadran Baladandayuthapani 3 5,  Scott Kopetz 4,  Judith S Sebolt-Leopold 6 7 8 9
Affiliations

Affiliations

  • 1 Department of Radiology, University of Michigan, Ann Arbor, MI, USA.
  • 2 MEKanistic Therapeutics, Inc., Ann Arbor, MI, USA.
  • 3 Department of Biostatistics, The University of Michigan School of Public Health, Ann Arbor, MI, USA.
  • 4 The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • 5 University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
  • 6 Department of Radiology, University of Michigan, Ann Arbor, MI, USA. jssl@med.umich.edu.
  • 7 MEKanistic Therapeutics, Inc., Ann Arbor, MI, USA. jssl@med.umich.edu.
  • 8 University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA. jssl@med.umich.edu.
  • 9 Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA. jssl@med.umich.edu.
  • # Contributed equally.
PMID: 38992135 DOI: 10.1038/s43018-024-00781-6
Abstract

Despite tremendous progress in precision oncology, adaptive resistance mechanisms limit the long-term effectiveness of molecularly targeted agents. Here we evaluated the pharmacological profile of MTX-531 that was computationally designed to selectively target two key resistance drivers, epidermal growth factor receptor and phosphatidylinositol 3-OH kinase (PI3K). MTX-531 exhibits low-nanomolar potency against both targets with a high degree of specificity predicted by cocrystal structural analyses. MTX-531 monotherapy uniformly resulted in tumor regressions of squamous head and neck patient-derived xenograft (PDX) models. The combination of MTX-531 with mitogen-activated protein kinase kinase or KRAS-G12C inhibitors led to durable regressions of BRAF-mutant or KRAS-mutant colorectal Cancer PDX models, resulting in striking increases in median survival. MTX-531 is exceptionally well tolerated in mice and uniquely does not lead to the hyperglycemia commonly seen with PI3K inhibitors. Here, we show that MTX-531 acts as a weak agonist of peroxisome proliferator-activated receptor-γ, an attribute that likely mitigates hyperglycemia induced by PI3K inhibition. This unique feature of MTX-531 confers a favorable therapeutic index not typically seen with PI3K inhibitors.

Figures
Products